CV Sciences (OTCMKTS:CVSI) Earns Overweight Rating from Analysts at Piper Jaffray Companies

Piper Jaffray Companies began coverage on shares of CV Sciences (OTCMKTS:CVSI) in a report released on Monday, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $5.00 target price on the stock. Piper Jaffray Companies also issued estimates for CV Sciences’ Q3 2019 earnings at $0.01 EPS, Q4 2019 earnings at $0.01 EPS, FY2019 earnings at ($0.04) EPS, Q1 2020 earnings at $0.01 EPS, Q2 2020 earnings at $0.02 EPS, Q3 2020 earnings at $0.03 EPS, Q4 2020 earnings at $0.04 EPS and FY2020 earnings at $0.10 EPS.

CVSI has been the subject of several other reports. Roth Capital initiated coverage on CV Sciences in a report on Thursday, May 16th. They issued a buy rating and a $9.00 target price for the company. Zacks Investment Research cut CV Sciences from a buy rating to a hold rating in a report on Tuesday, June 18th. Finally, Northland Securities restated a buy rating on shares of CV Sciences in a report on Thursday, May 9th.

OTCMKTS CVSI opened at $3.20 on Monday. The business has a fifty day moving average price of $3.91 and a 200 day moving average price of $4.72. CV Sciences has a one year low of $2.76 and a one year high of $9.20. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.43 and a current ratio of 3.20. The company has a market cap of $317.04 million, a P/E ratio of 35.50 and a beta of -0.50.

CV Sciences (OTCMKTS:CVSI) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.01 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. The firm had revenue of $16.85 million during the quarter, compared to the consensus estimate of $17.45 million. CV Sciences had a negative return on equity of 6.47% and a negative net margin of 3.29%. As a group, sell-side analysts predict that CV Sciences will post -0.04 EPS for the current fiscal year.

About CV Sciences

CV Sciences, Inc operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.

Featured Story: Why is momentum important to successful trading?

Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.